La vaccination contre le virus du papillome humain—un enjeu des soins infirmiers en oncologie?

Catriona Buick, Kelly Metcalfe

Abstract


Tous les ans, environ 1500 Canadiennes sont diagnostiquées du cancer du col de l’utérus et 581 d’entre elles mourront de la maladie (WHO/ICO Information Centre on HPV and Cervical Cancer (2007). La prévention du cancer du col de l’utérus est d’une énorme importance étant donnés les effets évidents de cette maladie sur la vie des femmes et de leurs proches, quels que soient leur culture, leur sexe, leur nationalité ou leur pays de résidence. À la lumière de la récente attention portée par les médias au vaccin contre le virus du papillome humain (VPH) et de la récente mise en marché de ce dernier au Canada, il est crucial que les infirmières en oncologie aient une excellente compréhension du VPH, de son rôle dans le développement du cancer du col de l’utérus et du vaccin contre le VPH. Le présent article présentera un bref aperçu du VPH et de son implication dans le développement du cancer du col utérin. Il fournira également de l’information sur le vaccin contre le VPH, sur les conséquences de ce dernier et sur la politique actuelle du Canada concernant la vaccination. Il abordera le rôle déterminant que peut jouer l’infirmière en oncologie, à titre d’éducatrice et de porteparole, sur le plan de la mise en oeuvre de cette vaccination et de son acceptation généralisée. Finalement, il abordera les répercussions du vaccin et les voies de recherche de demain.


Full Text:

PDF

References


Action Cancer Ontario. (2002). Programme ontarien de dépistage

du cancer du col de l’utérus : rapport sur le Programme,

–2000. (270831). Toronto, ON.

Action Cancer Ontario. (2004). Le virus du papillome humain

(VPH) et le cancer du col de l’utérus. Programme ontarien de

dépistage du cancer du col de l’utérus.

Agence de la santé publique du Canada (2007) La prévention du

virus du papillome humain (VPH) et le vaccin contre le VPH :

Questions et réponses. Récupéré le 12 juin 2007 à

h t t p : / / w w w. p h a c - a s p c . g c . c a / s t d - m t s / h p v - v p h /

hpv-vph-vaccine-fra.php

American Cancer Society. (2006). HPV Vaccine Fights Cervical

Cancer. CA: A Journal For Clinicians, 56, 249–250.

Arbyn, M., & Dillner, J. (2007). Review of current knowledge on

HPV vaccination: An appendix to the European Guideline For

Quality Assurance in Cervical Cancer Screening. Journal Of

Clinical Virology, 38, 189–197.

Association canadienne des infirmières en oncologie. (2001). Normes de

soins, rôles infirmiers en oncologie et compétences relatives aux

rôles infirmiers. Norme 3 : Autodétermination et prise de décisions.

Brotherton, J.M.L., Gold, M., Kemp, A.S., McIntyre, P.B., Burgess,

M.A., & Campbell-Lloyd, S. (2008). Anaphylaxis following

quadrivalent Human Papillomavirus vaccination. CMAJ, 179(6),

–533.

Burchell, A., Winer, R., de Sanjose, S., & Franco, E. (2006). Chapter

: Epidemiology and transmission dynamics of genital HPV

infection. Vaccine, S3/52–S3/61.

Cain, J., Denny, L., & Ngan, H.Y.S. (2007). Overcoming barriers to

eradication of cervical cancer: Women’s health and rights.

International Journal of Gynecology and Obstetrics, 97, 232–234.

Cancer Care Ontario. (2007). Ontario announces HPV vaccination

program. Retrieved December 12, 2007, from

http://www.cancercare.on.ca/OntarioCancerNewsArchives/

/index_703.htm

Casey, D. (2007). Nurses’ perception, understanding and experiences

of health promotion. Journal of Clinical Nursing, 16,

–1049.

Comeau, P. (2007). Debate begins over public funding for HPV

vaccine. Canadian Medical Association Journal, 176(7),

–913.

Dunne, E., & Markowitz, L. (2006). Genital Human Papillomavirus

infection. Emerging Infections, 43, 624–629.

Franco, E., & Harper, D. (2005). Vaccination against Human

Papillomavirus infection: A new paradigm in cervical cancer

control. Vaccine, 23, 2388–2394.

FUTURE 11 Study Group. (2007). Quadrivalent vaccine against

Human Papillomavirus to prevent high-grade cervical lesions. The

New England Journal of Medicine, 356(19), 1915–19.

Garnett, G., & Waddell, H. (2000). Public health paradoxes and the

epidemiological impact of an HPV vaccine. Journal of Clinical

Virology, 19, 101–111.

GlaxoSmithKline. (2006). Cervarix®, GSK’s candidate vaccine for

cervical cancer demonstrated sustained efficacy for up to 4.5

years and broader protection against cancer-causing HPV

types. Retrieved March 18, 2008, from http://www.gsk.com/

ControllerServlet?appId=4&pageId=402&newsid=806

Goldie, S., Kohli, M., Grima, D., Weinstein, M., Wright, T., Bosch,

X., & Franco, E. (2004). Projected clinical benefits and costeffectiveness

of a Human Papillomavirus 16/18 vaccine. Journal

of The National Cancer Institute, 96(8), 604–615.

Government of Nova Scotia. (2007). HPV immunization

launched. Retrieved June 24, 2007, from:

http://www.gov.ns.ca/news/details.asp?id=20070620002

Gullatte, M. (2001). Prevention, screening and detection. In S.

Otto, Oncology Nursing (4th ed., pp. 53–77). St. Louis: Mosby

Inc.

International Collaboration of Epidemiological Studies of Cervical

Cancer. (2006). Cervical carcinoma and reproductive factors:

Collaborative reanalysis of individual data on 16,563 women with

cervical carcinoma and 33,542 women without cervical carcinoma

from 25 epidemiological studies. International Journal of

Cancer, 119, 1108–1124.

Kahn, J., & Bernstein, D. (2005). Human Papillomavirus vaccines

and adolescents. Current Opinion in Obstetrics and

Gynecology, 17, 476–482.

Kane, M. (2006). Developing HPV vaccine in the industrial and

developing world: The role of the Ob-Gyn community.

International Journal of Obstetrics and Gynecology, 94(Suppl.

, S89–S94.

Koutsky, L., & Harper, D. (2006). Current findings from prophylactic

HPV trials. Vaccine, S3, 114–121.

Lai, C., Huang, H., Hsueh, S., Chao, A., Lin, C., Huang, S., et al.

(2006). Human Papillomavirus genotype in cervical cancer: A

population-based study. International Journal of Cancer, 120,

–2006.

Merck & Co. (2008). Gardasil—The only cervical cancer vaccine.

Retrieved March 18, 2008, from: http://www.gardasil.com/

Moreira, E., Oliveira, B., Neves, R., Costa, S., Karic, G., & Filho, J.

(2006). Assessment of knowledge and attitudes of young

unisured women toward Human Papillomavirus vaccination and

clinical trials. Journal of Pediatric Adolescence Gynecology,

, 81–87.

Moscicki, A., Schiffman, M., Kjaer, S., & Villa, L. (2006). Chapter 5:

Updating the natural history of HPV and anogenital cancer.

Vaccine, S3/42–S3/51.

Munoz, N., Castellsague, X., Berrington de Gonzalez, A., &

Gissmann, L. (2006). Chapter 1: HPV in the etiology of human

cancer. Vaccine, S3/1–S3/10.

Newall, A., Beutals, P., Wood, J., Edmunds, W., & MacIntyre, C.

(2007). Cost-effectiveness analyses of Human Papillomavirus

vaccination. The Lancet, 7, 289–296.

Parkin, D., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer

statistics, 2002. CA: A Cancer Journal For Clinicians, 55,

–108.

Perrin, K., Daley, E., Naoom, S., Packing-Ebuen, J., Rayko, H.,

McFarlane, M., & McDermott, R. (2006). Women’s reactions to

HPV diagnosis: Insights from in-depth interviews. Women And

Health, 43(2), 93–110.

Plummer, M., & Franceschi, S. (2002). Strategies for HPV

prevention. Virus Research, 89, 285–293.

Relevé des maladies transmissibles au Canada (2007). Comité

consultatif national de l’immunisation—Déclaration sur le

vaccin contre le virus du papillome humain.

http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07pdf/

acs33-02.pdf

Ritvo, P., Wilson, K., Wilms, D., & Upshur, R. (2005). Vaccines in the

public eye. Nature Medicine Supplement, 11(4), S20–S24.

Saslow, D., Castle, P., Cox, T., Davey, D., Einstein, M., Ferris, D., et

al. (2007). American Cancer Society guidelines for Human

Papillomavirus vaccine use to prevent cervical cancer and its

precursors. CA: A Cancer Journal For Clinicians, 57, 7–28.

Sherman, M., Schiffman, M., Strickler, H., & Hildesheim, A. (1998).

Prospects for a prophylactic HPV vaccine: Rationale and future

implications for cervical cancer screening. Diagnostic

Cytopathology, 18(1), 5–9.

Sideri M., & Mariani, L. (2008). The HPV vaccine in Italy: How to

put research data into practice. Let the debate begin! HPV

Today. Retrieved November 5, 2008, from

http://www.g-o-c.org/uploads/hpvtoday_oct_2008.pdf

Société canadienne du cancer. (2007). La Société canadienne du

cancer se réjouit du montant accordé à l’implantation du

vaccin anti-VPH dans le budget fédéral. Récupéré le 12 juin

à http://www.cancer.ca/ontario/about%20us/media%20

centre/od-media%20releases/canadian%20cancer%20society%20

applauds%20funding%20for%20hpv%20vaccine%20announced

%20in%20federal%20budget.aspx?sc_lang=fr-CA

De Vuyst, H., Steyaert, S., Renterghem, L., Claeys, P., Muchiri, L.,

Sitati, S., et al. (2003). Distribution of Human Papillomavirus in a

family planning population in Nairobi, Kenya. Sexually

Transmitted Diseases, 30(2), 137–141.

Williamson, A., Passmore, J., & Rybicki, E. (2005). Strategies for the

prevention of cervical cancer by Human Papillomavirus vaccine.

Best Practice and Research Clinical Obstetrics and

Gynecology, 19(4), 531–544.

WHO/ICO Information Centre on HPV and Cervical Cancer.

(2007). Human Papillomavirus and cervical cancer.

Summary report on HPV and cervical cancer statistics in

Canada. Retrieved March 12, 2008, from

www.who.int/hpvcentre

Zimet, G. (2006). Understanding and overcoming barriers to Human

Papillomavirus vaccine and acceptance. Current Opinion in

Obstetrics and Gynecology, 18(Suppl. 1), S23–S28.

Zimmerman, R. (2007). HPV vaccine and its recommendations, 2007.

The Journal of Family Practice, 56(2), S2–S5.


Refbacks

  • There are currently no refbacks.


Bookmark and Share